Janney Montgomery Scott Downgrades Innocoll (INNL) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
FBR Capital Downgrades Innocoll (INNL) to Market Perform
December 30, 2016 8:19 AM ESTFBR Capital downgraded Innocoll (NASDAQ: INNL) from Outperform to Market Perform with a price target of $2.00 (from $10.00) after the company received a Refusal to File letter from the United States Food and Drug Administration (FDA) for XARACOLL, the companys product candidate for the... More
JMP Securities Downgrades Innocoll (INNL) to Market Perform; XARACOLL Approval Delayed at Least 6-12 Months
December 30, 2016 7:15 AM ESTJMP Securities downgraded Innocoll (NASDAQ: INNL) from Market Outperform to Market Perform.
Analyst Jason Butler said the FDA refuse-to-file letter likely delays XARACOLL approval by at least 6-12 months.
"While we currently view the potential requirement for an... More
Innocoll AG (INNL) Receives Refusal to File Letter from FDA on XARACOLL NDA
December 29, 2016 5:03 PM ESTInnocoll (NASDAQ: INNL) received a Refusal to File letter from the United States Food and Drug Administration (FDA) for XARACOLL, the companys product candidate for the treatment of postsurgical pain.
Upon preliminary review, the FDA determined that the application,... More
